Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Radimmune Therapeutics

Request full access

Developing novel therapies for cancer

Burlingame, United StatesEdtech

About Radimmune Therapeutics

Radimmune Therapeutics, founded in 2015 by Paresh Ghelani, is a biotechnology firm focused on developing novel treatments for cancer. The company is headquartered in Menlo Park, California, and operates within the biopharmaceutical market, specializing in radioimmunotherapy (RIT). Its business model centers on the research and development of a proprietary technology platform to create new cancer therapies. Radimmune secured $13.6 million in a Series A funding round in August 2019.

The company's core product is a form of molecular targeted radiotherapy that employs monoclonal antibodies (mAbs) chemically linked to a radionuclide. This therapeutic agent is infused and designed to target a specific antigen within the cancer cell microenvironment, such as in melanoma. By binding to the target antigen, the treatment delivers focused radiation directly to tumor cells, which helps to minimize the toxic effects on surrounding healthy tissues. Radimmune is particularly focused on Alpha Emitting RIT, which uses alpha-emitting radionuclides linked to customized mAbs. This method is considered potent due to the high relative biologic effectiveness of alpha rays, which also have a very short path length in tissue, allowing for precision in targeting cancer cells.

The scientific founders, Ekaterina Dadachova and David Rickles, along with a team of advisors, provide strategic guidance for the company's research initiatives. In a significant step towards clinical trials, Radimmune partnered with Goodwin Biotechnology in late 2018 to manufacture its lead therapeutic candidate for a Phase I study in melanoma treatment. The company received a Small Business Innovation Research (SBIR) grant from the National Institutes of Health/National Cancer Institute (NIH/NCI) based on its preclinical results.

Source: Dealroom company data

Radimmune Therapeutics in the Burlingame ecosystem

Live from Dealroom

The Radimmune Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Burlingame HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Radimmune Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Radimmune Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.